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Abstract
Lipid peroxidation causes the generation of the neurotoxic aldehydes acrolein and 4-hydroxy-trans-2-nonenal (HNE). These products are
elevated in neurodegenerative diseases and acute CNS trauma. Previous studies demonstrate that mitochondrial class 2 aldehyde
dehydrogenase (ALDH2) is susceptible to inactivation by these alkenals. In the liver and brain another mitochondrial aldehyde dehydrogenase,
succinic semialdehyde dehydrogenase (SSADH/ALDH5A1), is present. In this study, we tested the hypothesis that aldehyde products of lipid
peroxidation inhibit SSADH activity using the endogenous substrate, succinic semialdehyde (SSA, 50 AM). Acrolein potently inhibited
SSADH activity (IC50 = 15 AM) in rat brain mitochondrial preparations. This inhibition was of an irreversible and noncompetitive nature. HNE
inhibited activity with an IC50 of 110 AM. Trans-2-hexenal (HEX) and crotonaldehyde (100 AM each) did not inhibit activity. These data
suggest that acrolein and HNE disrupt SSA metabolism and may have subsequent effects on CNS neurochemistry.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Excessive generation or decreased clearance of alde-
hydes in the CNS may result in neurotoxicity. One source
of aldehyde generation in the CNS is enzymatic oxidative
deaminations of amine neurotransmitters such as GABA
and dopamine leading to the generation of succinic
semialdehyde (SSA) and dihydroxyphenylacetaldehyde
(DOPAL), respectively. Experiments in vitro show that
DOPAL accumulation has cytotoxic effects through inhib-
ition of mitochondrial function [1]. Another source of
aldehydes in the CNS is oxidative damage to polyunsa-
turated fatty acid leading to the formation of alkenals that
include trans-2-hexenal (HEX), acrolein, and 4-hydroxy-
trans-2-nonenal (HNE) [2]. These alkenals, in particular,
HNE and acrolein, have numerous cytotoxic effects
including the inhibition of membrane transporters and
mitochondrial respiration through alkylation of nucleo-
philic groups [3]. Tissue levels of HNE and acrolein are
elevated in numerous neurodegenerative disorders [4–6].
These a,h-unsaturated aldehydes can potentially alter the
metabolism of products of neurotransmitter deamination.
For example, DOPAL is oxidized to dihydroxyphenylacetic
acid (DOPAC) by the cytosolic class 1 aldehyde dehydro-
genase (ALDH1) and the mitochondrial, class 2 aldehyde
dehydrogenase (ALDH2) [7]. In vitro, acrolein is a potent,
irreversible inhibitor of ALDH1 and ALDH2 in part by the
alkylation of the active site cysteine by the highly electro-
philic C3 carbon of acrolein [8]. HNE inhibits acetaldehyde
metabolism by ALDH2 even at 10-fold higher concentra-
tions of acetaldehyde over HNE through competitive inhib-
ition as well as irreversible inhibition by alkylation of
ALDH2 [9].
Disregulation of SSA metabolism is involved in CNS
disease. SSA is oxidized to succinic acid by the action of
the succinic semialdehyde dehydrogenase (SSADH,
ALDH5A1), an enzyme located within the mitochondrial
matrix that has high selectivity for SSA [10]. Genetic
SSADH deficiency in humans leads to severe neurodeve-
lopmental and other physiologic abnormalities [11]. This is
in part due to excessive concentrations of g-hydroxybuty-
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rate (GHB), a product of SSA reduction by succinic semi-
aldehyde reductase (SSAR/AKR7A2). SSAR expression is
elevated in the cerebral cortex of patients with Alzheimer’s
disease (AD) [12].
As opposed to the mitochondrial localization of SSADH,
immunolocalization studies in human and rat brain slices
show a perinuclear and cytoplasmic localization of SSAR.
Subcellular fractionation studies performed on rat liver
suggest that SSAR is associated with the Golgi apparatus
[13]. In human brain, SSAR is predominantly localized to
glial cells whereas SSADH, at least in rodents, is localized
to neurons [12,14]. Like other aldo-keto reductase family
members, SSAR is able to metabolize a,h-unsaturated
aldehydes like HNE and acrolein [15].
The oxidation of acetaldehyde by ALDH2 is inhibited by
HNE in the mitochondrial environment, demonstrating that
lipid peroxidation inhibits crucial metabolic pathways [9].
However, it is not known if the oxidation of SSA by
SSADH is similarly affected by aldehydes derived from
lipid peroxidation. In this work, we tested the hypothesis
that alkenal products of lipid peroxidation are inhibitors of
SSADH activity using a series of a,h-unsaturated aldehydes
with increasing chain length.
2. Materials and methods
2.1. Chemicals and reagents
All chemicals used were of the highest grade available.
SSA and NAD+ were purchased from Sigma Chemical Co.
(St. Louis, MO). HEX and crotonaldehyde were purchased
from Acros Chemical. Acrolein was purchased from Fluka.
HNE was a kind gift from Dr. V. Amarnath of Vanderbilt
University [16]. Glutathione was purchased from EM Sci-
ence and dithiothreitol from Fisher Chemical.
2.2. Preparation of rat brain mitochondria
Whole brain mitochondria (synaptic and non-synaptic)
were isolated from adult, male, Sprague–Dawley rats (Har-
lan) as described previously [17]. Isolation buffer consisted
of mannitol (0.21 M), sucrose (70 mM), HEPES (5 mM),
EGTA (1 mM), and bovine serum albumin (BSA 1 mg/ml)
with a final pH of 7.4 at 4 jC. Rats were deeply anesthetized
with ketamine (100 mg/kg) and xylazine (13 mg/kg), the
brains removed and homogenized. Homogenates (40 ml per
brain) were centrifuged at 3000 g for 2 min (4 jC) to
pellet nuclei and cellular debris. The supernatant was then
centrifuged at 12,000 g (4 jC) for 10 min. The pellet was
resuspended in 10 ml of homogenization buffer and 20 Al of
10% digitonin was added to disrupt the synaptosomes. The
suspension was then centrifuged as above. The pellet was
resuspended in buffer (10 ml) without BSA and centrifuged.
This final pellet was resuspended in 0.5 ml of buffer without
BSA. For experiments not involving intact mitochondria,
the final mitochondrial pellet was diluted to 50% glycerol
containing 10 mM dithiothreitol to preserve SSADH activ-
ity, aliquoted, and frozen at  80jC [18].
2.3. Respiratory measurements
Respiration was measured using an oxygen electrode
(YSI International) and oxygen consumption chamber
(Gilson Medical Electronics). Experiments were performed
at 37 jC. Assay media contained 125 mM KCl, 5 mM
MgCl2, 2 mM KPO4, and 5 mM HEPES–KOH (pH 7.4).
The complex I-linked substrate glutamate (5 mM) and
ADP (1 mM) were used to determine the respiratory
control ratio (RCR). State 4 respiration was taken as the
respiratory rate following the addition of glutamate 2 min
prior to the addition of ADP to stimulate state 3 respira-
tion. For experiments using intact mitochondria, the RCR
was 5 or higher.
2.4. Measurement of SSADH activity
Frozen mitochondria were thawed on ice with the addi-
tion of an equal volume of homogenization buffer consisting
of 20 mM sodium phosphate (pH 7.4 at 4 jC), 0.5% Triton
X-100, 1 mM diethylenetriaminepentaacetic acid (DEPA) to
chelate iron and calcium, and 50 AM 2,6-di-tert-butyl-4-
methylphenol (BHT) to limit lipid peroxidation. The mito-
chondria were resuspended using a Dounce tissue grinder
(Wheaton, Millville, NJ) using 10 strokes of the tight pestle.
The mitochondria were then passed over a G25 Sephadex
column equilibrated with homogenization buffer to remove
potential endogenous aldehydes.
SSADH activity was measured at 37 jC in 100 mM
sodium phosphate buffer (pH 7.4) using a modified pro-
cedure of Chambliss et al. [19]. Dithiothreitol or other thiol
reducing agents were not included due to their reactivity
with the alkenals tested. Measurements were performed
using a microplate format and an adjustable wavelength
microplate reader (SpectraMax 384 plus, Molecular Devi-
ces, Sunnyvale, CA). UV transparent, 96-well plates
(Greiner) were used. A 300-Al volume reaction was
performed that typically included 30 to 50 Ag of mito-
chondrial protein eluted from the G25 column. In these
assays, mitochondrial protein was added to the assay
buffer followed by the addition of NAD+ (1 mM) and
the background rate of NADH formation measured for 5
min. It was during this incubation period that the potential
aldehyde inhibitors were added. Following 5 min SSA (50
AM final) was added. Although SSA has a KM of 3.9 AM
for purified rat brain SSADH, preliminary experiments
(not shown) with lysed rat brain mitochondria demonstra-
ted an apparent KM of 9.1 AM for SSA and hence an
approximately fivefold greater amount of SSA (50 AM)
was used for activity studies [18]. This concentration of
SSA (50 AM) was not inhibitory. NADH formation was
measured as the increase in absorbance at 340 nm with an
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extinction coefficient of 6.22 mM 1. The pathlengths of
the assays were all normalized to 1 cm as part of the
capabilities of the microplate reader. The background rate
was subtracted from the SSA-stimulated rate to give the
resulting SSADH activity.
2.5. Statistical analyses
Analyses were performed using one-way analysis of
variance (ANOVA) with the Bonferroni post test or using
Student’s t test where appropriate.
3. Results
The first experiments were designed to determine the
relative efficacy of four alkenals, acrolein, HNE, HEX, and
crotonaldehyde (100 AM each, see Fig. 1 for structures), to
inhibit SSADH activity in disrupted mitochondria isolated
from rat brain. We deliberately chose to study SSADH
inhibition in a setting that would bias against finding
SSADH inhibition. First, the mitochondrial setting was used
with other mitochondrial proteins and nucleophilic groups
(such as those found on aminophospholipids and other
proteins) present in order to prevent bias against observing
inhibition against a purified protein only. NAD+ was
included in the incubation medium with these alkenals in
order to mimic the in situ condition. Previous studies have
shown that the presence of co-factor protects against inacti-
vation by a,h-unsaturated aldehydes [20]. Crotonaldehyde
and HEX did not significantly inhibit SSADH activity at
100 AM concentrations even with 10-min incubations and
were not studied further. Acrolein almost completely ablated
SSADH activity and HNE partially inhibited SSADH activ-
Fig. 1. Structure of SSA and the alkenals used in this study.
Fig. 2. Inhibition of SSADH activity by alkenal products of lipid
peroxidation. Alkenals (100 AM final concentration) were incubated with
mitochondrial homogenate and NAD+ (1 mM) for 5 min prior to the
addition of SSA (50 AM). The results (n= 6) are the meanF S.E. of assays
performed in triplicate using mitochondria derived from two separate
animals on 2 separate days. Results are expressed as the percent of control
reactions. The control rate of SSADH activity for day 1 was 10.7F 0.7
nmol/min/mg and for day 2 was 24.2F 1.3 nmol/min/mg of mitochondrial
protein. *P < 0.05, treated versus control using one-way analysis of
variance with a Bonferroni’s post test for comparison of groups.
Fig. 3. Inhibition curves of acrolein and HNE. Acrolein and HNE were
incubated at the given concentrations with mitochondrial homogenate and
NAD+ (1 mM) for 5 min prior to the addition of SSA (50 AM). The results
(n = 6) are the meanF S.E. of assays performed in triplicate using
mitochondria derived from two separate animals on 2 separate days.
Results are expressed as the percent of control reactions. The control rate of
SSADH activity for day 1 was 40.0F 0.7 nmol/min/mg and for day 2 was
42.7F 5.2 nmol/min/mg of mitochondrial protein.
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ity (Fig. 2). None of these aldehydes stimulated detectable
NADH formation.
Acrolein and HNE were studied further to determine the
IC50 of these compounds for inhibition of activity with SSA
as substrate following a 5-min incubation. Acrolein
inhibited SSADH activity with an IC50 of approximately
15 AM (Fig. 3A). The IC50 for HNE was approximately 110
AM (Fig. 3B). Increasing the incubation time for HNE or
acrolein to 10 min did not cause any further amounts of
inhibition; however, inhibition by acrolein was completed
by 2 min (not shown).
Because of the potent inhibition of SSADH activity by
acrolein, the type of inhibition was studied further. Com-
petition experiments with increasing doses of SSA showed
that acrolein inhibited SSADH activity in a noncompetitive
or irreversible manner (Fig. 4A). Experiments in which
mitochondria were exposed to acrolein followed by dilution
before activity measurements suggested that the inhibition
was mixed irreversible and noncompetitive (Fig. 4B). A
similar type of inhibition of rat ALDH2 by acrolein has been
observed [7].
We then examined whether glutathione would protect
SSADH activity from inactivation. In these experiments, a
fivefold excess of GSH over acrolein was able to prevent
acrolein-mediated inhibition (Fig. 5).
In the previous experiments, disrupted mitochondria
were exposed to acrolein. We next tested the hypothesis
that acrolein can inhibit SSADH activity when applied to
whole, nondisrupted mitochondria. Whole mitochondria,
with RCRs of 5 or greater, were exposed to 30 AM acrolein
for 5 min followed by the addition of a fivefold excess
glutathione, pelleting and washing at 4 jC, before determi-
nation of SSADH activity. Even under these conditions,
SSADH activity was decreased to 35% of control values
(Fig. 6). These data demonstrate that acrolein may have
 
Fig. 4. Acrolein inhibits SSADH activity in an irreversible and non-
competitive manner. (A) Mitochondria were exposed to acrolein (15 AM;
filled triangle) for 5 min followed by the addition of increasing
concentrations of SSA. Control mitochondria (no acrolein) are denoted
by the filled square. Note that even at 20-fold more SSA (300 AM) than
acrolein, no increase in activity was observed. (B) Nondiluted mitochondria
were exposed to 0 or 30 AM acrolein in a test tube (TT) for 5 min followed
by a 15-fold dilution in assay buffer and addition of SSA (50 AM) resulting
in a final concentration of 2 AM acrolein. For comparison, diluted mito-
chondrial homogenate was exposed to either 0 or 2 AM acrolein for 5 min
prior to the addition of SSA (50 AM). Note that restoration of full SSADH
activity did not occur in the samples in which the acrolein was initially
at 30 AM but then diluted to 2 AM. The results (n= 6) in (A) are the
meanF S.E. of assays performed in triplicate using mitochondria derived
from two separate animals on 2 separate days. Results are expressed as the
percent of control reactions. The results in (B) are the mean of three
independent assays performed on one preparation of rat brain mitochondria.
The control test tube rate (34.3F 1.3 nmol/min/mg) and control cuvette
rates (32.1F1.2 nmol/min/mg) were not significantly different. Analyses in
(B) were performed using one-way analysis of variance with a Bonferroni’s
post test for comparison of groups. *P < 0.05 for 30 AM TT versus 0 AM
TT, 0 AM cuvette, and 2 AM cuvette. yP < 0.05 for 2 AM cuvette versus 0
AM cuvette.
Fig. 5. Protection of SSADH activity by glutathione. Acrolein (20 AM) was
incubated with mitochondrial homogenate and NAD+ (1 mM) for 5 min
with or without glutathione (GSH, 100 AM) prior to the addition of SSA (50
AM). The results (n= 6) are the meanF S.E. of assays performed in
triplicate using mitochondria derived from two separate animals on 2
separate days. Results are expressed as the percent of control reactions. The
control rate of SSADH activity for day 1 was 27.7F 1.4 nmol/min/mg and
for day 2 was 35.1F1.2 nmol/min/mg of mitochondrial protein. Analyses
were performed using one-way analysis of variance with a Bonferroni’s
post test for comparison of groups. *P< 0.05 for acrolein versus control,
GSH, and GSH:acrolein; yP< 0.05 for GSH:acrolein versus acrolein alone,
GSH, and control.
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directly permeated the mitochondrial inner membrane or
altered the mitochondrial inner membrane to such an extent
to allow greater diffusion of subsequent acrolein molecules
into the matrix and inactivate SSADH. The latter is dis-
counted by previous experiments showing that acrolein does
not induce uncoupling of respiration as would be expected if
the mitochondrial membrane was permeant to acrolein [17].
4. Discussion
SSA metabolism plays an important role in CNS phys-
iology. In this work, we tested the hypothesis that a,h-
unsaturated aldehyde products of lipid peroxidation are
inhibitors of SSA metabolism by SSADH. Our experiments,
using a series of physiologically relevant alkenals and
isolated rat brain mitochondria, demonstrate that acrolein
and HNE inhibit SSADH activity and that acrolein inhibits
SSADH activity in an irreversible and noncompetitive
manner.
The relationship between the structure of these alkenals
and their ability to inhibit SSADH under these conditions
was not predictable. It is surprising that HNE inhibited
SSADH activity to the extent measured given the structure–
function relationship of the alkenals used. From the lack of
inhibition by crotonaldehyde or HEX, HNE would have
been predicted to be a relatively poor inhibitor as well. We
speculate that the inhibition of SSADH in part may be due
to the C4 hydroxyl group of HNE that to some fashion may
mimic the carboxyl group of SSA as both are four carbons
distant from the aldehyde and are electronegative (see Fig.
1). A positive charged residue of SSADH has been postu-
lated to interact with the carboxylate of SSA from data using
the methyl ester of SSA [21].
Acrolein rapidly forms covalent adducts with numerous
mitochondrial nucleophilic groups and would be expected to
affect numerous enzymatic activities [17]. In these present
studies, 30 AM acrolein inhibited SSADH activity to approx-
imately 35% of control values with intact mitochondria.
Under similar conditions, acrolein inhibits mitochondrial
respiration to 60% of control rates [17] and demonstrates
that even in the mitochondrial environment, numerous targets
of acrolein inactivation exist.
These data suggest that SSADH activity may be a target
of inactivation in situations of elevated oxidative stress and
lipid peroxidation. Markers for lipid peroxidation, including
acrolein and HNE, are elevated in the affected areas of
cerebral cortex of patients with AD [22]. However, whether
SSADH activity is altered in AD is not clear. One study
observed no change in SSADH activity between control
individuals and patients with AD [23]. However, the mean
postmortem interval for the tissue used was over 10 h.
In summary, our data demonstrate that acrolein and HNE
are potent inhibitors of SSADH activity in mitochondria
isolated from rat brain. Decreases in SSADH activity may
lead to corresponding elevations in GHB levels through
reduction of SSA, similar to what is observed in SSADH
deficiency. These data suggest that acrolein and HNE can
disrupt SSA metabolism and have subsequent effects on
CNS neurochemistry.
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